SHIFT Newsroom · UK

Semaglutide (Wegovy, Ozempic and Rybelsus): Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus)

By SHIFT AI Newsroom · Published 10 September 2026

How we prepare and check newsroom articles · Report a correction

The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus). This update is relevant to UK patients and healthcare professionals, as Semaglutide is licensed and available in the UK for the treatment of certain conditions.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

This update is relevant to UK patients and healthcare professionals, as Semaglutide is licensed and available in the UK for the treatment of certain conditions

Known facts

The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus)

Sources and evidence

MHRA — Source date: 5 February 2026

← Back to SHIFT Newsroom